Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 19;345(11):1600-8.
doi: 10.1016/j.carres.2010.05.006. Epub 2010 May 15.

Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates

Affiliations

Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates

Joanna Kubler-Kielb et al. Carbohydr Res. .

Abstract

There is no licensed vaccine for the prevention of shigellosis. Our approach to the development of a Shigella vaccines is based on inducing serum IgG antibodies to the O-specific polysaccharide (O-SP) domain of their lipopolysaccharides (LPS). We have shown that low molecular mass O-SP-core (O-SPC) fragments isolated from Shigella sonnei LPS conjugated to proteins induced significantly higher antibody levels in mice than the full length O-SP conjugates. This finding is now extended to the O-SPC of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1. The structures of O-SPC, containing core plus 1-4 O-SP repeat units (RUs), were analyzed by NMR and mass spectroscopy. The first RUs attached to the cores of S. flexneri 2a and 6 LPS were different from the following RUs in their O-acetylation and/or glucosylation. Conjugates of core plus more than 1 RU were necessary to induce LPS antibodies in mice. The resulting antibody levels were comparable to those induced by the full length O-SP conjugates. In S. dysenteriae type 1, the first RU was identical to the following RUs, with the exception that the GlcNAc was bound to the core in the beta-configuration, while in all other RUs the GlcNAc was present in the alpha-configuration. In spite of this difference, conjugates of S. dysenteriae type 1 core with 1, 2, or 3 RUs induced LPS antibodies in mice with levels statistically higher than those of the full size O-SP conjugates. O-SPC conjugates are easy to prepare, characterize, and standardize, and their clinical evaluation is planned.

PubMed Disclaimer

Figures

Figure 1
Figure 1
BioGel P-10 gel filtration profiles of 2% acetic acid hydrolyzed Shigellae LPSs. F1 – O-SP; more then 10 RU; F2, F3 – core + avr. 2–5 O-SP RU; F4 - core + avr. 1 O-SP RU.
Figure 2
Figure 2
Structures of Shigellae O-SPC fragments of core plus one O-SP repeat unit (RU).
Figure 3
Figure 3
Fragment of COSY (green-cyan) and TOCSY (red) spectra of the core-RU from the LPSs of S. flexneri O2a (top) and S. flexneri O6 (bottom), illustrating O-acetylation of the terminal rhamnose residues (T). Proton signals at the acetylation site are shifted to low field.
Figure 4
Figure 4
Integration of the proton signals of S.flexneri 2a 1 O-SPC fractions for the determination of the average number of O-SP repeat units (RU). Rha methyl signals in 1H-NMR spectra (1.16–1.31 ppm) in the O-SP relative to the anomeric signals of the core α-Gal K (5.90 ppm) and α-Glc L (5.52 ppm) were used. F1-O-SP; F2-core-3RU; F3-core-2RU; F4-core-1RU; F5-core.
Figure 5
Figure 5
Integration of the anomeric signals of S. dysenteriae 1 O-SPC fractions for the determination of the average number of O-SP repeat units (RU). The anomeric signal of the terminal Rha T (5.08 ppm) relative to that of the substituted Rha T (5.11 ppm) was used. F1-O-SP; F2-core-3RU; F3-core-2RU; F4-core-1RU.

Similar articles

Cited by

References

    1. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Bull. World Health Organ. 1999;77:651–666. - PMC - PubMed
    1. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Nat. Rev. Microbiol. 2007;5:540–553. - PMC - PubMed
    1. Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R. Vaccine. 2010;28:2231–2235. - PMC - PubMed
    1. Guerrant RL, Kirchhoff LV, Shields DS, Nations MK, Leslie J, de Sousa MA, Araujo JG, Correia LL, Sauer KT, McClelland KE. J. Infect. Dis. 1983;148:986–997. - PubMed
    1. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Infect. Immun. 1999;67:782–788. - PMC - PubMed

Publication types

LinkOut - more resources